{"id":"NCT01240746","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Quadrivalent Influenza Vaccine Among Children","officialTitle":"Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2011-12","completion":"2012-02","firstPosted":"2010-11-15","resultsPosted":"2014-01-14","lastUpdate":"2015-07-14"},"enrollment":4363,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative","otherNames":["Fluzone®"]},{"type":"BIOLOGICAL","name":"Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative","otherNames":[]},{"type":"BIOLOGICAL","name":"Quadrivalent Influenza Vaccine, No Preservative","otherNames":[]}],"arms":[{"label":"Group 1: Licensed 2010-2011 TIV","type":"ACTIVE_COMPARATOR"},{"label":"Group 2: Investigational TIV","type":"EXPERIMENTAL"},{"label":"Group 3: Investigational QIV","type":"EXPERIMENTAL"}],"summary":"The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain (B1), and the investigational TIV containing the alternate B (B2) strain in children.\n\nPrimary Objective:\n\nTo demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the alternate B strain) as assessed by geometric mean titer (GMT) ratios for each of the four virus strains separately among children aged 6 months to less than 9 years of age\n\nSecondary Objective:\n\nTo demonstrate superiority of antibody responses to each B strain in QIV compared with antibody titers following vaccination with the TIV that does not contain the corresponding B strain, as assessed by GMT ratios and seroconversion rates.\n\nObservational Objective:\n\nTo describe the safety profile of QIV among subjects 6 months to less than 9 years of age, as assessed by solicited injection site and systemic adverse events (AEs) collected for 7 days post-vaccination, unsolicited adverse events collected from 21 days post-vaccination, and adverse events of special interest and serious adverse events (SAEs) collected from Visit 1 to Visit 2.","primaryOutcome":{"measure":"Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants","timeFrame":"Day 28 post final vaccination","effectByArm":[{"arm":"Study Group 1 (Trivalent Influenza Vaccine)","deltaMin":1096,"sd":null},{"arm":"Study Group 3 (Investigational Quadrivalent Influenza Vaccine)","deltaMin":1124,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":67,"countries":["United States"]},"refs":{"pmids":["24445833"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":734},"commonTop":["Injection site pain","Injection site erythema","Myalgia","Malaise","Injection site Swelling"]}}